Deer­field and ARCH back a new $200M SPAC run by Cal­i­for­nia VC firm

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Two promi­nent life sci­ences firms have teamed up to spon­sor a new SPAC that made its way to Nas­daq on Tues­day evening.

Deer­field Man­age­ment and ARCH Ven­ture Part­ners are back­ing the blank check com­pa­ny known as DA32 Life Sci­ence Tech Ac­qui­si­tion Corp., which priced at $200 mil­lion Mon­day, the firms an­nounced. The pair is team­ing up with Cal­i­for­nia-based VC firm Sec­tion 32, whose man­ag­ing part­ner Steven Kaf­ka will run the SPAC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER